BLAINJECTIONINJECTABLE
Approved
Sep 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
OVIDREL (choriogonadotropin alfa) by Merck & Co. is clinical pharmacology the physicochemical, immunological, and biological activities of recombinant hcg are comparable to those of placental and human pregnancy urine-derived hcg. First approved in 2000.
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OVIDREL (choriogonadotropin alfa) is a recombinant human chorionic gonadotropin (hCG) analog administered by subcutaneous injection for ovulation induction in assisted reproductive technology (ART). It mimics the luteinizing hormone (LH) surge to trigger final follicle maturation and oocyte meiosis resumption in women undergoing fertility treatment. The drug is used after FSH-induced follicular development has reached sufficient maturity.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting team focus shifting toward lifecycle extension or transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY The physicochemical, immunological, and biological activities of recombinant hCG are comparable to those of placental and human pregnancy urine-derived hCG. Choriogonadotropin alfa stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of…
Worked on OVIDREL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.